- Home
- » Tags
- » Ridaforolimus
Top View
- Mtor Inhibition/Targeting in Solid Tumors
- NDO Home | Contact | Register for NDO Access
- Mtor Signaling in Cancer and Mtor Inhibitors in Solid Tumor Targeting Therapy
- Strategies for the Management of Adverse Events Associated with Mtor Inhibitors
- Supplemental Material 1
- Mtor Signaling in Metabolism and Cancer
- Università Degli Studi Di Catania
- Supplementary Fig. S1
- Rapalogs in Viral Cancers
- Drug Eruptions Associated with Tumor Therapy: Great Imitators
- Pharmaceutical Clinical Trials in New York in State Taxes and More Than $646 Million in Federal • Clinical Trials Are Responsible for 45 to 75 Percent of Taxation
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- A Phase 2, Multicenter, Open-Label Study of BGJ398 in Patients with Recurrent Resectable Or Unresectable Glioblastoma
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Identification of Precision Treatment Strategies for Relapsed/ Refractory Multiple Myeloma by Functional Drug Sensitivity Testing
- Strategies for the Management of Adverse Events Associated with Mtor Inhibitors
- A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients with Advanced Solid Tumors
- Phase I Study for Ridaforolimus, an Oral Mtor Inhibitor, in Japanese Patients with Advanced Solid Tumors
- Pdf/2009-10/Firmagon - Ct-6725.Pdf 58
- International Nonproprietary Names for Pharmaceutical Substances (INN)
- Changelog (In Alphabetical Order of the Value Set) Value Set Code Description Change
- 210311 Wild Guided Report.Indd
- Molecular Blueprints for Antitumor Drugs
- Research in Your Backyard Developing Cures, Creating Jobs
- Intravenous Ascorbate and Oncologic Agents
- Supplementary Information Natural Product and Natural Product Derived Drugs in Clinical Trials
- Role of Mtor Inhibition in Preventing Resistance and Restoring Sensitivity to Hormone-Targeted and HER2-Targeted Therapies in Breast Cancer Ingrid Mayer, MD
- Progress in the Chemotherapeutic Treatment of Osteosarcoma (Review)
- Study Protocol and Results
- WHO Drug Information Vol
- Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-Of-Care Therapy for Appendicular Osteosarcoma
- Clinical Update
- Clinical and Preclinical Treatment Aspects of Castration Resistant Prostate Cancer (CRPC)
- Télécharger (1MB)
- Ol'sin('HE Related U.S
- Gel Formulations for Local Drug Release
- Ut Scc 110A Ut Scc 21 Ut Scc 49 Ut Scc 74A
- A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery Through Drug Repurposing
- Stefania Staibano Editor Prostate Cancer: Shifting from Morphology to Biology Prostate Cancer: Shifting from Morphology to Biology
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Formulation Development of Anti-Cancer Drugs by Yunqi Zhao Submitted to the Graduate Degree Program in Pharmaceutical Chemistry
- An Unbiased Oncology Compound Screen to Identify Novel
- A Retrospective Study of Patients with Malignant Pecoma Receiving Treatment with Sirolimus Or Temsirolimus: the Royal Marsden Hospital Experience
- Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
- International Patent Classification: C12N 15/62 (2006.01) C07K 14/725
- Pharmacokinetic Evaluation of a DSPE-PEG2000 Micellar Formulation of Ridaforolimus in Rat
- Dual Mtor/PI3K Inhibition Limits PI3K-Dependent Pathways
- Phase I Study of Oral Ridaforolimus in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumor Cancers Hye Sook Chon1, Sokbom Kang2, Jae K
- Ridaforolimus (AP23573; MK-8669), a Potent Mtor Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
- Gemcitabine and Rapamycin Exhibit Additive Effect Against Osteosarcoma by Targeting Autophagy and Apoptosis
- Änderungen Im Erstattungskodex (EKO) Ab Jänner 2021 Informationsstand Jänner 2021
- (12) United States Patent (10) Patent No.: US 8,852,590 B2 Sathyanarayanan Et Al
- Abteilung Fachberatung Medizin Recherche Und Synopse Der